The Joint Association of Septicemia and Cerebrovascular Diseases with In-Hospital MortalityAmong Patients with Left Ventricular Assist Device in the United States
Currently, about 6.2 million adults in the US are reported to have heart failure, and this prevalence is expected to increase by 46% by 2030.1 The prognosis of advanced heart failure especially, advanced systolic heart failure, has improved tremendously with the advent of implantable mechanical circulatory support devices such as left ventricular assist device (LVAD) which is often used as a bridge to heart transplantation or as a destination therapy.2,3 Indeed, LVAD has improved the 1-year survival of patients with advanced heart disease from 52% to about 85%.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Jessica Lovelace, Obadeh Shabaneh, Noah De La Cruz, Damilola R. Owoade, Chike C. Nwabuo, Nandini Nair, Duke Appiah Source Type: research
More News: Cardiology | Heart | Heart Disease | Heart Failure | Heart Transplant | Hospitals | Neurology | Stroke | Transplants | USA Health